Peter B Ostergren
Overview
Explore the profile of Peter B Ostergren including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
136
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Madsen C, Fuglo D, Pedersen M, Broholm R, Ostergren P, Bisbjerg R, et al.
J Nucl Med
. 2025 Jan;
66(2):223-229.
PMID: 39778967
Prostate-specific membrane antigen (PSMA) PET/CT is increasingly used for primary staging in prostate cancer (PC), mainly because of its improved accuracy in detecting lymph node metastases compared with conventional imaging....
2.
Ternov K, Fode M, Sonksen J, Bisbjerg R, Lindberg H, Palapattu G, et al.
Clin Genitourin Cancer
. 2024 Sep;
22(6):102200.
PMID: 39244832
Introduction: The purpose of this study was to investigate the association between baseline androgen concentrations and outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line enzalutamide or...
3.
Ternov K, Sonksen J, Fode M, Lindberg H, Kistorp C, Bisbjerg R, et al.
Eur J Cancer
. 2022 Jun;
171:75-84.
PMID: 35709600
Introduction: Enzalutamide and abiraterone acetate plus prednisone (AAP) have similar efficacy in metastatic castration-resistant prostate cancer (mCRPC). Herein, we compare fatigue, health-related quality-of-life (HRQoL) and metabolic changes in men with...
4.
Guldbaek M, Fode M, Jensen C, Sonksen J, Ostergren P
BJU Int
. 2021 Sep;
128(4):428-430.
PMID: 34581479
No abstract available.
5.
Nolsoe A, Jensen C, Ostergren P, Fode M
Int J Impot Res
. 2020 Dec;
33(4):428-438.
PMID: 33318637
In this narrative review we summarize neglected side effects of curative intended treatment for prostate cancer. They include climacturia, arousal incontinence (AI), orgasmic disturbances such as altered orgasmic sensation, anorgasmia,...
6.
Fode M, Jensen C, Ostergren P
Eur Urol
. 2020 Oct;
79(1):60-61.
PMID: 33087292
No abstract available.
7.
Fode M, Nolsoe A, Jacobsen F, Russo G, Ostergren P, Jensen C, et al.
Sex Med
. 2020 Jun;
8(3):408-413.
PMID: 32593674
Introduction: Many patients seek information online including on social media. Aim: To assess the quality of information regarding erectile dysfunction (ED) in YouTube videos. Methods: We searched "erectile dysfunction" on...
8.
Fode M, Jensen C, Ostergren P
Int J Impot Res
. 2020 Mar;
32(5):549-550.
PMID: 32203430
No abstract available.
9.
Nolsoe A, Ostergren P, Jensen C, Fode M
Nat Rev Urol
. 2019 Oct;
16(11):633-634.
PMID: 31575989
No abstract available.
10.
Jensen C, Fode M, Ostergren P, Sonksen J
Eur Urol
. 2019 Aug;
76(5):637-638.
PMID: 31447078
No abstract available.